Tumour cells apoptosis factor

Drug Profile

Tumour cells apoptosis factor

Alternative Names: 84AA–API 14AA; Nerofe

Latest Information Update: 09 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immune System Key
  • Class Antineoplastics; Cardiovascular therapies; Peptide hormones
  • Mechanism of Action Angiogenesis inhibitors; Apoprotein stimulants; Apoptosis stimulants; Immunomodulators; Interleukin 1 receptor-like 1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Haematological malignancies
  • Discontinued Myocardial infarction

Most Recent Events

  • 01 Mar 2017 Immune System Key plans a phase II trial for Acute myelogenous leukaemia and Myelodysplastic syndromes in Romania(NCT03059615)
  • 09 May 2016 Tumour cells apoptosis factor is still in phase I trials for Solid tumours in Israel
  • 09 May 2016 Tumour cells apoptosis factor is still in preclinical trials for Haematological malignancies in Israel
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top